Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Neoplasms, Experimental

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Peripheral T-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Inflammatory Agents

Anti-Infective Agents

Etoposide

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Prednisone

Vincristine

Etoposide phosphate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Tubulin Modulators

Antimitotic Agents

Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.

Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.

Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Chidamide

Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.

Jun Zhu, Dr.

Yuqin Song, Dr.

Jun Zhu, MD

Weiping Liu, MD

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients.

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

The rate of patients who achieve complete remission after the treatment.

The total proportion of patients with complete response（CR）and partial response（PR）.

Time from treatment until disease progression or death.

From the date of inclusion to date of death, irrespective of any cause.

Peking University International Hospital

Shandong Tumor Hospital

Jiangxi Provincial Cancer Hospital

Peking University

Director of lymphoma department

Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.

Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Time from treatment until disease progression or death

Time from treatment until death from any cause

Hebei Medical University Fourth Hospital

Director

Symptoms and General Pathology

Infections

Recurrence

Epstein-Barr Virus Infections

Virus Diseases

Communicable Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.

Li Zhang, MD

Wenfeng Fang, MD

Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with recurrent and metastatic Epstein-Barr virus (EBV)-associated solid tumors.

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

the total proportion of patients with complete response（CR）and partial response（PR）

the total proportion of patients with complete response（CR）, partial response（PR）and Stable Disease（SD）

Time from first documented complete response (CR) or partial response (PR) until time of progression.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients	NCT03617432	Experimental Tu...	Chidamide Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone	18 Years - 70 Years	Peking University
Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma	NCT03611231	Experimental Tu...	Chidamide	18 Years - 70 Years	Peking University
Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors	NCT03494634	Experimental Tu...	Chidamide	18 Years - 70 Years	Sun Yat-sen University
Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors	NCT03494634	Experimental Tu...	Chidamide	18 Years - 70 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for experimental tumor